Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
16 déc. 2024 07h00 HE
|
Seres Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
09 déc. 2024 07h00 HE
|
Seres Therapeutics, Inc.
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy...
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
22 nov. 2024 07h00 HE
|
Seres Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive...
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
13 nov. 2024 07h00 HE
|
Seres Therapeutics, Inc.
SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile...
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
06 nov. 2024 07h00 HE
|
Seres Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and...
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
30 sept. 2024 17h15 HE
|
Seres Therapeutics, Inc.
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high...
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
26 sept. 2024 16h01 HE
|
Seres Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its...
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
13 sept. 2024 07h00 HE
|
Seres Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor...
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
12 sept. 2024 07h00 HE
|
Seres Therapeutics, Inc.
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia,...
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
13 août 2024 07h00 HE
|
Seres Therapeutics, Inc.
SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September VOWST asset sale to provide $175M cash infusion, less approximately $20M in settlement of net obligations...